Epidemiological characteristics of COVID-19 patients in Samarinda, East Kalimantan, Indonesia

Introduction. Coronavirus Disease (COVID-19) is caused by SARS-CoV-2 infection. Indonesia announced the first COVID-19 case on 2 March 2020. East Kalimantan has been determined as the new capital of Indonesia since 2019. This makes Samarinda as the capital of East Kalimantan has been focused for its capability of handling COVID-19 patients. We report the epidemiological characteristics and immunofluorescence assay results of these patients. Methods. All patients with positive confirmed COVID-19 by RT-PCR were admitted to hospitals and quarantine center in Samarinda. We retrospectively analyzed data from the daily report of the Samarinda City and East Kalimantan Health Office information system. Results. By June 25, 2020, 64 patients had been identified as having positive confirmed COVID-19. The mean age of the patients was 37.3 {+/-} 13.8 years. Most of the patients were men (57 [90.6%] patients). Thirty-nine COVID-19 patients were imported cases with a history of traveling from South Sulawesi. Most of the patients were admitted to the Quarantine Center of Samarinda City. The mean duration from the first hospital admission for isolation to discharge was 25.6 {+/-} 13.1 days. There was only one death case of COVID-19 patients in Samarinda. There were the highest confirmed cases of COVID-19 in Samarinda in early June 2020. There was a declining trend in the age of COVID-19 patients and the duration of isolation time in the hospital. Discussion. Imported cases still contributed to the increase of COVID-19 cases in Samarinda. Younger age of COVID-19 patients was more involved in frequent mobility which makes them cause the spread of the disease. Activation of the national reference laboratory for the COVID-19 examination in Samarinda has reduced the length of time patients treated in hospitals. Conclusion. The epidemiological characteristics of COVID-19 patients show the ability of local governments to deal with this pandemic. This can be seen from the low case fatality rate in Samarinda.

which was then named SARS-CoV-2 (7). Until the end of June 2020, the USA, Brazil, and Russia 51 were the countries for the most COVID-19 cases in the world. There are more than 10 million 52 positive confirmed cases worldwide (8). 53 On March 2, 2020, Indonesia announced the first case of COVID- 19 (9 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 11, 2020. Indonesia. Although individual informed consent was not required for this study, all data were 66 handled to protect patient confidentiality and privacy. 67

Data Source 68
All data contained in all COVID-19 case records in the Samarinda City and East Kalimantan 69 Health Office information system through the end of June 25, 2020, were extracted from the 70 system. No sampling was done to achieve a predetermined study size and no eligibility criteria 71 were used (all cases were included). is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 11, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 11, 2020. On the 12th week (June 3-9, 2020) there were the highest confirmed cases reaching 1.9 100 patients per day. This number has gradually declined in the following weeks (Figure 1). There 101 is a declining trend in the age of COVID-19 patients, who are initially over 40 years old, later 102 in their 30s (Figure 2). There is also a declining trend in the duration of admission time in the 103 hospital, which initially can last more than 3 weeks, later to be around one week only ( Figure  104 3). CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 11, 2020. ; https://doi.org/10.1101/2020.07.10.20151175 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 11, 2020. Indonesia. This laboratory serves the examination of reference specimens from the provinces 150 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 11, 2020. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 11, 2020. ; https://doi.org/10.1101/2020.07.10.20151175 doi: medRxiv preprint